• AR and ARv7 as Prognostic Drivers in TNBC: Evidence from EPI

  2026-05-15

  This study delineates the prognostic significance of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), linking their expression to worse survival and increased metastasis. It further demonstrates that targeting AR/ARv7 with N-terminal domain inhibitors like EPI-001 modulates key metastatic and EMT pathways in TNBC models, offering mechanistic insight into new intervention strategies.

• Dihydrotestosterone (DHT): Mechanistic Evidence & Research U

  2026-05-15

  Dihydrotestosterone (DHT) is a potent endogenous androgen and agonist of the androgen receptor. It upregulates EGFR and ERBB2 signaling in AR-positive cancer models and confers functional and molecular benefits in ALS mouse models. APExBIO’s DHT B8214 provides a rigorously characterized tool for dissecting androgen receptor pathways in translational research.

• Optogenetic RNA-Releasing Protein Enables Light-Controlled G

  2026-05-14

  A recent study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that acts as a gene switch, enabling precise, light-dependent translational regulation in mammalian cells. This innovation offers a platform for on-demand gene therapies, with particular potential in treating chronic metabolic and retinal diseases requiring controlled transgene activity.

• Pomalidomide (CC-4047): Precision Tools for Myeloma Research

  2026-05-14

  Pomalidomide (CC-4047) enables high-fidelity immunomodulation and tumor microenvironment studies in hematological malignancy research. This guide delivers actionable workflow enhancements, troubleshooting expertise, and data-driven insights to maximize reproducibility and impact in advanced multiple myeloma models.

• MAPK10 Suppresses NSCLC Metastasis via KRT16 Phosphorylation

  2026-05-13

  This study identifies mitogen-activated protein kinase 10 (MAPK10) as a suppressor of non-small cell lung cancer (NSCLC) metastasis. Through phosphorylation-dependent ubiquitination of keratin 16 (KRT16), MAPK10 promotes proteasomal degradation of KRT16, revealing a potential axis for therapeutic targeting and prognostic biomarker development in NSCLC.

• EPZ5676: Applied DOT1L Inhibition for Precision Epigenetic A

  2026-05-13

  EPZ5676, a potent and highly selective DOT1L inhibitor, is transforming workflows in leukemia and fibrosis research. This article translates recent breakthroughs and expert protocols into actionable steps, enabling scientists to maximize the value of EPZ5676 in both cancer epigenetics and kidney fibrosis models.

• QRICH1 Drives HBV-Induced HMGB1 Secretion and Hepatic Fibros

  2026-05-12

  This study identifies QRICH1 as a key effector of endoplasmic reticulum (ER) stress that amplifies hepatitis B virus (HBV)-mediated HMGB1 translocation and secretion in hepatocytes. These findings clarify the molecular crosstalk between ER stress, QRICH1, and HMGB1 in hepatic fibrosis, providing new mechanistic insight relevant for liver disease research.

• Novel PDK4 Inhibitors: Advances for Metabolic Disease Resear

  2026-05-12

  This article reviews a recent study identifying a new class of pyruvate dehydrogenase kinase 4 (PDK4) inhibitors with promising oral efficacy for metabolic diseases. The research details structural innovation, in vitro and in vivo validation, and offers implications for future therapeutic development.

• Honokiol-Induced Paraptosis in APL: Role of mTOR and MAPK Si

  2026-05-11

  This study demonstrates that honokiol induces paraptosis-like cell death in acute promyelocytic leukemia (APL) cells through activation of mTOR and MAPK pathways. The findings highlight a nonapoptotic, caspase-independent mechanism involving ER stress and proteasome inhibition, providing new avenues for therapeutic intervention in APL resistant to conventional treatments.

• Entinostat (MS-275): Applied Protocols in Cancer Cell Analys

  2026-05-11

  Entinostat (MS-275) enables selective HDAC1/3 inhibition for robust cancer cell proliferation assays and apoptosis studies. This guide translates reference-backed methods and troubleshooting strategies into actionable, stepwise workflows using APExBIO’s trusted reagent.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Models

  2026-05-10

  This study demonstrates that the fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2′-deoxyuridine (EdU) to induce telomere attrition and mitotic catastrophe in colorectal cancer cells. The findings offer mechanistic insight into how DNA-targeting combinations can enhance telomerase-targeted strategies and inform future research on telomerase inhibitors in oncology.

• Inducing Dormancy in Mammalian Embryos via mTOR Inhibition

  2026-05-09

  This protocol-driven study establishes a robust and reversible in vitro method for inducing a diapause-like dormant state in mammalian embryonic cells by pharmacologically inhibiting mTOR. The approach offers a noninvasive, scalable alternative to traditional surgical models, enabling high-throughput investigation of developmental dormancy and expanding research capabilities in assisted reproductive technologies.

• Translating mRNA Mechanisms to Reliable Reporter Assays

  2026-05-09

  This article provides translational researchers with mechanistic insight and practical guidance for leveraging ARCA EGFP mRNA (5-moUTP) as a next-generation, polyadenylated reporter for fluorescence-based transfection control. It contextualizes advances in mRNA engineering, storage, and immune evasion, while bridging recent literature with strategic recommendations for robust, reproducible results.

• Nanoplastics and Cadmium Trigger Apoptosis via IP3R/Ca2+/STA

  2026-05-08

  This study demonstrates that co-exposure to polystyrene nanoplastics and cadmium induces pronounced apoptosis in intestinal cells, mediated by the IP3R/Ca2+/STAT3 pathway. The work advances understanding of environmental contaminant synergy and highlights the utility of calcium chelation for dissecting complex cell signaling events.

• Gepotidacin in Antibacterial Research: Applied Protocols and

  2026-05-07

  Gepotidacin (GSK2140944) is reshaping antibacterial research with its unique dual topoisomerase inhibition, offering powerful solutions against resistant pathogens. This article translates the latest clinical and experimental findings into actionable workflows, optimization tips, and troubleshooting strategies for maximizing data quality in bacterial DNA replication inhibition studies.

451 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page